Bladder cancer: issues requiring further research
https://doi.org/10.21886/2308-6424-2024-12-4-155-158
Abstract
The article discusses issues related to the treatment of patients diagnosed with locally advanced bladder cancer.
About the Authors
I. A. Rozhkov
Blokhin National Medical Research Centre for Oncology
Russian Federation
Competing Interests:
Russian Federation
Ivan A. Rozhkov.
Moscow
Competing Interests:
None
P. V. Bulychkin
Blokhin National Medical Research Centre for Oncology
Russian Federation
Competing Interests:
Russian Federation
Pyotr V. Bulychkin — Cand.Sc.(Med).
Moscow
Competing Interests:
None
References
1. Ding H, Fan N, Ning Z, Ma D. Trimodal Therapy vs. Radical Cystectomy for Muscle-Invasive Bladder Cancer: A Meta-Analysis. Front Oncol. 2020;10:564779. DOI: 10.3389/fonc.2020.564779
2. Dracham CB, Kumar N, Kumar S, Elangovan A, Yadav BS, Mavuduru RS, Lal A, Gupta PK, Kapoor R. A phase II study of neoadjuvant chemotherapy followed by organ preservation in patients with muscle-invasive bladder cancer. Asian J Urol. 2022;9(3):318-328. DOI: 10.1016/j.ajur.2021.06.006
3. Swinton M, Mariam NBG, Tan JL, Murphy K, Elumalai T, Soni M, Ferrera A, Richardson C, Walshaw R, Mistry H, Ramani V, Song Y, Birtle A, Henry A, Chan J, Hoskin P, Choudhury A. Bladder-Sparing Treatment With Radical Dose Radiotherapy Is an Effective Alternative to Radical Cystectomy in Patients With Clinically Node-Positive Nonmetastatic Bladder Cancer. J Clin Oncol. 2023;41(27):4406-4415. DOI: 10.1200/JCO.23.00725
4. Tan MP, Harris V, Warren-Oseni K, McDonald F, McNair H, Taylor H, Hansen V, Sharabiani M, Thomas K, Jones K, Dearnaley D, Hafeez S, Huddart RA. The Intensity-Modulated Pelvic Node and Bladder Radiotherapy (IMPART) Trial: A Phase II Single-Centre Prospective Study. Clin Oncol (R Coll Radiol). 2020;32(2):93-100. DOI: 10.1016/j.clon.2019.07.017
5. Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, Kalofonos H, Radulović S, Demey W, Ullén A, Loriot Y, Sridhar SS, Tsuchiya N, Kopyltsov E, Sternberg CN, Bellmunt J, Aragon-Ching JB, Petrylak DP, Laliberte R, Wang J, Huang B, Davis C, Fowst C, Costa N, Blake-Haskins JA, di Pietro A, Grivas P. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2020;383(13):1218-1230. DOI: 10.1056/NEJMoa2002788
6. Joshi M, Tuanquin L, Zhu J, Walter V, Schell T, Kaag M, Kilari D, Liao J, Holder SL, Emamekhoo H, Sankin A, Merrill S, Zheng H, Warrick J, Hauke R, Gartrel B, Stein M, Drabick J, Degraff DJ, Zakharia Y. Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023. J Immunother Cancer. 2023;11(2):e006551. DOI: 10.1136/jitc-2022-006551
Review
For citations:
Rozhkov I.A., Bulychkin P.V. Bladder cancer: issues requiring further research. Urology Herald. 2024;12(4):155-158. (In Russ.) https://doi.org/10.21886/2308-6424-2024-12-4-155-158
Views:
485
Email this article 
